Commercial anti-CD19 CAR T cell therapy fo patients with relapsed/refractory aggressive B cell lymphoma in a European center.

https://pubmed.ncbi.nlm.nih.gov/32744738/ Authors: Sesques P, Ferrant E, Safar V, Wallet F, Tordo J, Dhomps A et al. Am J Hematol 2020;95(11):1324-1333.

Efficacy and safety of tisagenlecleucel in Japanese adult patients with relapsed/refractory diffuse large B-cell lymphoma.

https://pubmed.ncbi.nlm.nih.gov/32448949/ Authors: Goto H, Makita S, Kato K, Tokushige K, Fujita T, Akashi K et al. Int J Clin Oncol 2020;25(9):1736-1743.

Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.

https://pubmed.ncbi.nlm.nih.gov/32888407/ Authors: Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnason J et al. Lancet 2020;396(10254):839-852.